Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial

OBJECTIVE: Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1α) and IL-1β; these cytokines are thought to play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP. METHODS: This multicentre, open-label study...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Allan L, Lin, David, Cremer, Paul C, Nasir, Saifullah, Luis, Sushil Allen, Abbate, Antonio, Ertel, Andrew, LeWinter, Martin, Beutler, Anna, Fang, Fang, Paolini, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Heart Failure and Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925818/
https://www.ncbi.nlm.nih.gov/pubmed/33229362
http://dx.doi.org/10.1136/heartjnl-2020-317928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925818/
https://www.ncbi.nlm.nih.gov/pubmed/33229362
http://dx.doi.org/10.1136/heartjnl-2020-317928

Ejemplares similares